Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes. 10k shares bought at ~ $0.19, loss of $619 so far. Slower in developing its algorithm and publicly disclosing its customer list than CDIO(also 10k shares bought at $0.42, STCG) who discloses its customers like Cleveland Clinic? No worries. I think we already know who some of HSCS customers are or will be.
CDMO just completed a large new plant for making complex molecules. Currently sells at $ 7.50/share. Overall, our 55k shares in 2 accounts are now profitable, LTCG. Methinks we have seen a bottom in 52 week range of ~ $4-21/share. Good series of 4 slides were recently posted by djohn on CDMO IHub site showing exterior and interior views of new plant where new and old customers(HALO is one) of CDMO gathered in late January 2024. Substantial insider and fund buying like AMRN. Far better buy than recent NVO buy of CTLT, IMO.
Others: NWBO, AGEN, CDIO, AVXL, WRAP, AUPH, BMR, GRCL, IOVA, XERS, VYGR in no particular order.
What do you see as the main focus of that 3M healthcare unit? Consumer goods like Kenvue? Will 3M retain a substantial equity position like JNJ did with Kenvue? Are market conditions such that 3M views the spinoff as a good way to pay down debt, or obtain funds for further innovation in the medical device sector or pharmaceutical/biotech sector? Funds for M/A with a target in mind?
Hmmm. Time flies. Look at my posts on February 7, not last week.
Mike, Gus: Best official sites are the courts in which litigation is pending, like CAFC ( on appeal from J. Andrew’s dismissal of Hikma from Amarin’s patent infringement suit in D. Delaware, or D. New Jersey(Trenton) where Dr. Reddy’s antitrust suit against Amarin is still in discovery stage though a schedule for expert reports to be submitted has been posted by the magistrate. See my post from this past week, Tuesday or Wednesday. I have printed major documents like Complaints, Answers, and all Briefs filed in those cases (free pdfs, no page fee to court reporter). I have no further update today.
Update: VCEL closed at $49.20 per share hitting a high of $49.91/share. Currently our 12k shares of VCEL are fighting it out with 755 shares of NVDA for highest market value in a TDA taxable account. Both are LTCG with cost basis already removed.
OT: Speaking of what improved results portend for AMRN, look at what a collaboration with NVDA has done for BMR. Our shares of BMR closed Friday ~ $2/share. Today those shares hit a high near $35/share, and are trading at $18-24/share up ~ 1000% in a partial day of trading. A PR from BMR today is the cause. I don’t recall seeing anything like that except when AMRN ascended to over $20/share a few years ago.
Thanks for that additional information that you read that is important to both Sarissa and other shareholders of AMRN.
What other entities has Rubric Capital Management (David Rosen) invested in? Patent based pharmaceutical? Generic pharmaceutical? Both? TEVA? Is Rubric interested in M/A of ANIP with/by TEVA? PAR in India? Other generics that may have interest in patent protected technology?
FTC voiced no objection to merger of IMGN with Abbvie. Merger expected to complete around 2/12/2024.
Merger expect to be completed next week, 2/12/2024, after FTC voiced no objection
What news is driving over 16 million shares traded in IMGN today. Shares trade at $31.23.
I am referring to your second, alternative suit that originated in Delaware.
Settlement is one of the alternatives that I listed in #421215.
The Fed.Cir. has published pdfs showing the days set for oral argument for the remainder of 2024 and for all of 2025. No specific cases are designated to be argued in those days, generally occurring the first week in a given month. 5-6 cases per day. En banc cases I will not talk about today.
Recall that the Court has not assigned new cases to Circuit Judge Newman; thus the Court is operating with 11 Circuit Judges plus its retired judges who are willing to sit on a panel. I have seen no sign of a visiting judge being designated to sit.
Currently there is no oral argument listed for Amarin v. Hikma in an updated CAFC February calendar or in a new March calendar. There could be further updates or news of a confidential settlement. OTOH, the parties may still be in line for an argument slot on a first come basis after submission of the necessary paperwork.
NVO buys CTLT to increase capacity for production of weight loss drug Wegovy. Purchase price = $11.5 Billion cash.
Per TDA, VKTX will report/discuss 4th quarter and year-end 2023 financial results on February 7 at 4:30 pm. A general corporate update will also be discussed.
Was the AMRN CFO form 4 filing the only one? It looked like 3 separate filings by different people to me.
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
I read your quote. Dr Gottlieb was on CNBC-TV at 2:30 pm today, discussing LLY and NVO pipelines and additional advantages/diseases to be obtained from treatments using respective weight loss drugs. Earlier, BMY/MRK patent cliffs were featured, with additional M/A activity discussed to diversify respective pipelines to treat additional diseases.
A good match between your quote and above discussion, IMO. Additional patent protection and reasonable M/A cost favor AMRN.
It’s about time to check the CAFC calendar to see whether the February oral argument calendar has been updated and the March oral argument calendar has been published.
Do we know what TEVA has done with that rather large amount of EPA that was delivered to Vancouver or Seattle ports some weeks ago? I believe I asked #sleven if he could trace where it went; I recall he could not.
Thermofisher CEO will be on CNBC-TV later today. Maybe some insights there.
Zimmer and Stryker are doing more surgical procedures that usually require pain relief and inflammation reducing meds. Has CDMO been in that field? How about bacteria and virus fighting meds, newly discovered or conventional?
Look at a 5-year chart. AMRN was in the $18-20 range. Then consider all the approvals since, not extant when Dr. Bhatt released preliminary results at AHA in Chicago. I agree with others who are looking for a $18-20 buyout. A petition to the FDA Commissioner, a cardiologist, just might force generics to make a label change: “This product is not approved for use in treating cardiovascular diseases.” Stay tuned.
Does that conform with bfiest’s links that I thought said Avid sold and the respective funds acquired. Maybe a mistake if the 2 funds did reduce their CDMO positions.
Thanks for those links from State Street and Altravue. Substantial purchases by each fund. At $6.94, it looks like our 55,000 shares in 2 accounts have regained profitability. We missed the grand opening of the new facilities this past week.
Note appointment of Dr. V. Ramjee, a cardiovascular expert, as Strategic Advisor to CDIO. Background: Mount Sinai School of Medicine, Emory and U. Pennsylvania Hospitals. Does Amarin and its cardiovascular experts have previous/current contact with Dr. Ramjee that could be useful in increasing Vascepa use in the United States? I am still thinking of a collaboration between Amarin(Vascepa treatment) and CDIO(CVD diagnostic)
Amarin requested a jury trial when it filed its complaint alleging patent infringement by Hikma in Delaware in 2020. A motion to dismiss filed by Hikma was granted by Judge Andrews, now on appeal to CAFC with no time yet set for oral arguments. You appear to be unaware of that case.
Kiwi, there are 4–6 “generic Vs”. Are you stating that one of the “new” generic Vs is actually a rebottled/relabeled Brand Vascepa? Do you, or anyone else, have proof of that position? It sounds like a good way of getting rid of older, dated, expiring inventory. What FDA regulations permit that maneuver?
DOI: 10.1056/NEJMoa230836
Traverse Clinical Trial, NCT03518034, AbbVie
N Engl J Med 2024; 203-11 and 267
There were a lot of preliminary votes by AHA society experts and members in 2019 and later. Preliminary votes are nice but don’t count. Does your visual graph now reflect actual society votes as of 2022-2023?
If I may interrupt, it appears to be a committee of experts at AHA staffed by experts who are either not sufficiently expert or don’t meet often enough to vote Vascepa into the appropriate guidelines. ADA was far better in late 2019. As a T1 diabetic, I visited ADA HQ in Alexandria, Va. I was told by the executive secretary that Vascepa had already been placed in ADA guidelines. BTW, my PCP is not a cardiologist but is a former NIH research M.D. who had no difficulty in prescribing Vascepa for me in late 2012. I was his first patient for whom he prescribed Vascepa. Recently he told me that he now has more patients on V than the 20 he estimated a few years ago.My co-pay continues to be $9 or $15 for a 3-month supply of Vascepa.
We have 500 shares in each of 2 accounts. Both are profitable, entry ~ $4 in the IRA, LTCG. XBI, IBB negative today. No worries, but Fed bears watching, eh?
Off > $3 from your post 2 weeks later. Trading at $7.12 at 1:50 pm today. News? None that I see.
HALO turned positive mid-day. Anybody listen to their conference call this morning? Takeda received FDA approval for its Enhanze-enhanced therapy AH yesterday. This should help CDMO.
I had bought 2000 AMRN, 1000 PHUN, 200 ACXP in a new joint account that I had established last year with the IRA RMD cash derived from PFE/SGEN merger.
Avid Bioservices(CDMO) has already invested heavily, both in its manufacturing plants in Tustin and a new virus/gene plant near John Wayne airport in California. HALO is a prime customer; CDMO supplies bulk material to HALO for use in its ENHANZE device that enables subcutaneous injection of products produced by Roche in Europe and JNJ.
MLK holiday. Markets closed.
The CAFC revised/updated its calendar of case arguments today. I found no Amarin v. Hikma listed for January or February 2024.